Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis
- 1 September 2004
- journal article
- Published by Elsevier in Value in Health
- Vol. 7 (5) , 554-568
- https://doi.org/10.1111/j.1524-4733.2004.75007.x
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis * Commentary: Evaluating disease modifying treatments in multiple sclerosisBMJ, 2003
- Cost-utility of interferon β 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosisThe European Journal of Health Economics, 2003
- Long Term Treatment of Multiple Sclerosis with Interferon-?? May Be Cost EffectivePharmacoEconomics, 2000
- A profile of multiple sclerosis: The New York State Multiple Sclerosis ConsortiumMultiple Sclerosis Journal, 1999
- Survey of multiple sclerosis in Northern CaliforniaMultiple Sclerosis Journal, 1999
- A comprehensive assessment of the cost of multiple sclerosis in the United StatesMultiple Sclerosis Journal, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Newer Versus Older Treatments for Relapsing-Remitting Multiple SclerosisDrug Safety, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- The natural history of multiple sclerosis: a regional study with some longitudinal data.Journal of Neurology, Neurosurgery & Psychiatry, 1992